Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results entities : Incyte corporation save search
Incyte to Report First Quarter Financial Results - April 11, 2024
Published: 2024-04-11 (Crawled : 21:00) - biospace.com/
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.62%
H: 1.17%
C: -0.76%
first report financial results
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | News | $97.755 0.49% 1.1M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $18.48 0.6% 110K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | News | $18.06 0.11% 96K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: -0.6%
H: 0.45%
C: 0.08%
MRUS | $40.995 0.43% 310K
|
Health Technology
|
| O: 2.3%
H: 0.58%
C: -2.69%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
business year update financial results
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.215 -1.23% 420K
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
XNCR | $18.48 0.6% 110K
|
Health Technology
|
| O: -3.56%
H: 2.91%
C: -3.34%
MOR | News | $18.06 0.11% 96K
|
Health Technology
|
| O: -0.4%
H: 0.23%
C: -0.46%
MGNX | $15.835 -2.43% 170K
|
Health Technology
|
| O: -5.25%
H: 2.94%
C: 2.18%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
financial
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-01-23 (Crawled : 14:00) - biospace.com/
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.37%
H: 0.75%
C: 0.23%
report financial results
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
Published: 2023-12-18 (Crawled : 00:00) - prnewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: 1.25%
H: 0.0%
C: 0.0%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: -0.03%
H: 0.06%
C: -2.67%
ibi362 obesity publication communications chinese results
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 480
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: -0.2%
H: 1.7%
C: 1.3%
rient-16 treatment results study
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
MRUS | $40.995 0.43% 310K
|
Health Technology
|
| O: 3.51%
H: 9.56%
C: 9.56%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.52%
H: 1.38%
C: 1.11%
business update financial results
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-10-31 (Crawled : 00:00) - biospace.com/
TAK | News | $13.215 -1.23% 420K
|
Health Technology
|
| O: 1.05%
H: 0.74%
C: 0.74%
XNCR | $18.48 0.6% 110K
|
Health Technology
|
| O: -0.41%
H: 2.1%
C: 1.11%
MOR | News | $18.06 0.11% 96K
|
Health Technology
|
| O: 4.23%
H: 0.12%
C: -1.97%
MGNX | $15.835 -2.43% 170K
|
Health Technology
|
| O: 0.0%
H: 2.13%
C: 1.16%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: -0.39%
H: 4.09%
C: 3.8%
financial results
Incyte to Report Third Quarter Financial Results - October 10, 2023
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.48%
H: 1.39%
C: 0.51%
report financial results
Innovent Announces 2023 Interim Results and Business Updates
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.39%
H: 0.37%
C: -0.6%
business results
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
Published: 2023-08-09 (Crawled : 13:00) - biospace.com/
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: -0.11%
H: 1.29%
C: 0.67%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.08%
H: 2.08%
C: 1.3%
DCPH | $14.65 -0.14% 78K
|
Health Technology
|
| O: 4.95%
H: 2.5%
C: 1.18%
pharmaceuticals financial results
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
Published: 2023-08-08 (Crawled : 03:00) - prnewswire.com
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
ibi363 antibody cancer preclinical results
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
Published: 2023-08-07 (Crawled : 21:00) - globenewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 11.43%
H: 6.32%
C: 3.08%
MRUS | $40.995 0.43% 310K
|
Health Technology
|
| O: 3.79%
H: 1.72%
C: -11.69%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
business update financial results
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-08-01 (Crawled : 15:00) - biospace.com/
TAK | News | $13.215 -1.23% 420K
|
Health Technology
|
| O: -2.23%
H: 2.28%
C: 1.34%
XNCR | $18.48 0.6% 110K
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
REPL | $6.27 -2.34% 110K
|
Health Technology
|
| O: 2.63%
H: 1.14%
C: -2.65%
MOR | News | $18.06 0.11% 96K
|
Health Technology
|
| O: -0.14%
H: 4.77%
C: 4.77%
MGNX | $15.835 -2.43% 170K
|
Health Technology
|
| O: 0.0%
H: 4.19%
C: 2.31%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 2.75%
H: 0.44%
C: -2.72%
financial results
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Published: 2023-07-24 (Crawled : 11:00) - prnewswire.com
SNDX | $20.73 -1.14% 110K
|
Health Technology
|
| O: 8.18%
H: 2.39%
C: -5.35%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.17%
H: 0.37%
C: -1.24%
agave-201 disease positive topline trial results
Incyte to Report Second Quarter Financial Results - July 11, 2023
Published: 2023-07-11 (Crawled : 13:00) - biospace.com/
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.44%
H: 1.16%
C: 1.09%
report financial results
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-05-10 (Crawled : 13:00) - biospace.com/
SYRS | $5.135 -0.1% 34K
|
Health Technology
|
| O: 0.0%
H: 15.7%
C: 10.29%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
update financial results
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ABBV | News | $168.51 -0.61% 920K
|
Health Technology
|
| O: -0.21%
H: 0.32%
C: -0.07%
ZLAB | $15.61 3.24% 190K
|
Health Technology
|
| O: 4.89%
H: 6.5%
C: 1.13%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.17%
H: 0.07%
C: -0.17%
NVCR | $12.24 1.54% 350K
|
Health Technology
|
| O: 1.11%
H: 1.89%
C: 0.97%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -2.41%
H: 5.41%
C: 3.75%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 1.07%
H: 1.21%
C: 0.62%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
BPMC | $92.51 0.24% 160K
|
Health Technology
|
| O: 1.36%
H: 0.13%
C: -1.89%
results
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
Published: 2023-05-08 (Crawled : 00:00) - prnewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: -0.38%
H: 2.06%
C: 1.53%
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
INCY | $51.4 -0.48% 380K
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
rient-31 lung lancet respiratory cancer cell plus results study
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $1.88 60.68% 98M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.